ValuEngine upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a report released on Friday.

A number of other brokerages have also weighed in on AUPH. BidaskClub upgraded shares of Aurinia Pharmaceuticals from a hold rating to a buy rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price target on shares of Aurinia Pharmaceuticals and gave the company a buy rating in a report on Monday, October 1st. HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, September 26th. Finally, Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 24th. Two analysts have rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $11.95.

Shares of AUPH opened at $5.54 on Friday. Aurinia Pharmaceuticals has a 1-year low of $4.41 and a 1-year high of $6.69. The stock has a market cap of $468.42 million, a P/E ratio of -6.02 and a beta of 2.22.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Aurinia Pharmaceuticals had a negative net margin of 7,280.85% and a negative return on equity of 36.10%. The company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.07 million. On average, equities analysts forecast that Aurinia Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of AUPH. Jane Street Group LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at about $182,000. Stanley Laman Group Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $276,000. Creative Planning raised its holdings in shares of Aurinia Pharmaceuticals by 8.2% in the 2nd quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock valued at $964,000 after purchasing an additional 13,000 shares in the last quarter. Ironwood Investment Management LLC raised its holdings in shares of Aurinia Pharmaceuticals by 18.0% in the 2nd quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after purchasing an additional 33,279 shares in the last quarter. Finally, Cornerstone Wealth Management LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $2,000,000. Institutional investors and hedge funds own 25.27% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: Stop Order

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.